Gatenby Piers A C, Ramus James R, Caygill Christine P J, Shepherd Neil A, Watson Anthony
UK National Barrett's Oesophagus Registry (UKBOR), University Department of Surgery, Royal Free and University College Medical School, London, UK.
Scand J Gastroenterol. 2008;43(5):524-30. doi: 10.1080/00365520701879831.
In the USA, detection of intestinal metaplasia is a requirement for enrollment in surveillance programmes for dysplasia or adenocarcinoma in columnar-lined oesophagus. In the UK, it is believed that failure to detect intestinal metaplasia at index endoscopy does not imply its absence within the columnarized segment or that the tissue is not at risk of neoplastic transformation. The aim of this study was to investigate the factors predicting the probability of detection of intestinal metaplasia in the columnarized segment.
Demonstration of intestinal metaplasia was analysed in 3568 biopsies of non-dysplastic columnar-lined oesophagus from 1751 patients from 7 centres in the UK. Development of dysplasia and adenocarcinoma was analysed in 322 patients without intestinal metaplasia and compared with that in 612 patients with intestinal metaplasia.
Intestinal metaplasia was more commonly detected in males than in females (odds ratio 1.244), longer segment length (10.3% increase per centimetre) and increasing number of biopsies taken (24% increase per unit increase). After 5 years of follow-up, 54.8% of patients without intestinal metaplasia at index endoscopy demonstrated intestinal metaplasia, and 90.8% after 10 years. There was no significant difference in the rate of development of dysplasia or adenocarcinoma between patients with or without intestinal metaplasia detection at index endoscopy.
Detection of intestinal metaplasia is subject to significant sampling error. It increases with segment length and number of biopsies taken. In the majority of patients, if sufficient biopsies are taken over time, intestinal metaplasia will be demonstrated. The decision to offer surveillance should not be based upon the presence or absence of intestinal metaplasia at index endoscopy as the risk of dysplasia and adenocarcinoma is similar in both groups.
在美国,检测出肠化生是柱状上皮化生食管发育异常或腺癌监测计划入选的一项要求。在英国,人们认为在初次内镜检查时未检测出肠化生并不意味着在柱状化节段内不存在肠化生,也不意味着该组织没有发生肿瘤转化的风险。本研究的目的是调查预测在柱状化节段检测出肠化生可能性的因素。
对来自英国7个中心的1751例患者的3568份非发育异常的柱状上皮化生食管活检标本进行肠化生分析。对322例无肠化生患者和612例有肠化生患者的发育异常和腺癌发生情况进行分析并比较。
男性比女性更常检测出肠化生(优势比1.244),节段长度越长(每厘米增加10.3%)以及活检标本数量增加(每增加一个单位增加24%)时,肠化生检出率越高。随访5年后,初次内镜检查时无肠化生的患者中有54.8%出现肠化生,10年后为90.8%。初次内镜检查时检测出或未检测出肠化生的患者之间,发育异常或腺癌的发生率无显著差异。
肠化生的检测存在显著的抽样误差。其随着节段长度和活检标本数量的增加而增加。在大多数患者中,如果随着时间推移获取足够的活检标本,将会检测出肠化生。是否提供监测的决定不应基于初次内镜检查时是否存在肠化生,因为两组中发育异常和腺癌的风险相似。